Phase 2 N=19 Laparoscopic Hyperthermic Intraperitoneal Chemoperfusion (HIPEC) for Metastatic Gastric Cancer
Gastrointestinal Cancer
Primary: Overall Survival (OS) After Hyperthermic Intraperitoneal Chemotherapy — 30.2 Months
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=51 A Study to Investigate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Efficacy of Risdiplam (RO7034067) in Type 2 and 3 Spinal Muscular Atrophy (SMA) Participants
Muscular Atrophy, Spinal
Primary: Part 1: Selected Part 2 Dose of Risdiplam for Participants With a Body Weight (BW) of >/=20kg — 5 milligram (mg)
Phase 2 N=1,066 Phase IIb Safety and Efficacy Study of Different Oral Doses of BAY94-8862 in Subjects With Worsening Chronic Heart Failure and Left Ventricular Systolic Dysfunction and Either Type 2 Diabetes Mellitus With or Without Chronic Kidney Disease or Chronic Kidney Disease Alone
Heart Failure
Primary: Percentage of Participants With a Relative Decrease in NT-proBNP of More Than 30% From Baseline to Day 90 — 37.2; 30.9; 32.5; 37.3 Percentage of participants — p=0.8771
Phase 2 N=165 Combining Varenicline and Naltrexone for Smoking Cessation
Nicotine Dependence · Alcohol Use Disorder
Primary: Number of Participants With Expired Carbon Monoxide Level <=5ppm — 22; 37 Participants
Phase 2 N=32 Phase 2 Pilot Trial of Subjects With Complex Non-healing Diabetic Foot Ulcers Treated With Standard Care Plus Cryopreserved Umbilical Cord Allograft (TTAX01)
Non-healing Wound · Non-healing Diabetic Foot Ulcer · Diabetic Foot Infection
Primary: Number of Subjects With Complete Wound Healing — 16 participants
Phase 2 N=733 A 6-week Dose Ranging Study of CHF 5259 pMDI in Subjects With Chronic Obstructive Pulmonary Disease
COPD · Chronic Obstructive Pulmonary Disease
Primary: Change From Baseline in FEV1 AUC(0-12h) Normalized by Time at Week 6 — 0.070; 0.118; 0.153; 0.147 Litres — p=0.037
Phase 2 N=113 Effects and Safety of OPK-88003 Dose Escalation in Type 2 Diabetes Subjects
Type 2 Diabetes Mellitus
Primary: Change in HbA1c in Subjects With Type 2 DM — -0.25; -1.47 mmols/mol
Phase 2 N=98 Radiation Therapy in Treating Patients With Stage I or Stage II Non-Small Cell Lung Cancer
Lung Cancer
Primary: Incidence of AE Grade 3 or Higher Toxicity — 24; 26 Participants
Phase 2 N=84 CHOCOlate MeLatonin for AdolescenT MigrainE
Migraine
Primary: Change in Mean Visual Analog Scale (VAS) Score — -2.3; -2.7 cm
Phase 2 N=181 A Study to Evaluate the Efficacy, Safety, and Tolerability of Guselkumab for the Treatment of Participants With Moderate to Severe Hidradenitis Suppurativa (HS)
Hidradenitis Suppurativa
Primary: Percentage of Participants Achieving Hidradenitis Suppurativa Clinical Response (HiSCR) at Week 16 — 38.7; 50.8; 45.0 percentage of participants — p== 0.166
Phase 2 N=283 Ponatinib in Participants With Resistant Chronic Phase Chronic Myeloid Leukemia (CP-CML) to Characterize the Efficacy and Safety of a Range of Doses
Myeloid Leukemia, Chronic, Chronic Phase
Primary: Percentage of Participants With Molecular Response (MR2: <=1% Breakpoint Cluster Region-Abelson Transcript Level) as Measured by the International Scale (BCR-ABL1IS) at…
Phase 2 N=18 NKTR-102 in Combination With Cetuximab in Patients With Refractory Solid Tumors (Phase 2a) and Metastatic or Locally Advanced Colorectal Cancer (Phase 2b)
Tumor · Colorectal Cancer
Primary: Number of Patients With Dose Limiting Toxicities — 0; 1; 1; 1 Participants
Phase 2 N=83 NKTR-102 Versus Irinotecan in Patients With Second-Line, Irinotecan-Naïve, KRAS Mutant, Colorectal Cancer
Colorectal Cancer
Primary: Kaplan-Meier Estimate of PFS by Central Radiological Review: ITT Population — 4.0; 2.8 months — p== 0.07
Phase 2 N=178 Study to Evaluate the Safety and Efficacy of NKTR-102 in Patients With Metastatic or Locally Advanced Ovarian Cancer
Tumor · Ovarian Cancer
Primary: Primary: Objective Response Rate (ORR) by Response Evaluation Criteria in Solid Tumors (RECIST): Primary Efficacy Population — 14.4; 14.4 Percentage of Patients
Phase 2 N=164 Chemotherapy Based on Positron Emission Tomography Scan in Treating Patients With Stage I or Stage II Hodgkin Lymphoma
Lymphoma
Primary: Progression-Free Survival (PFS) at 36-Months for Patients Who Received 4 Cycles of ABVD — .91 proportion of patients